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Abstract
Objectives In response to the escalating epidemic of
cardiovascular disease (CVD) in the Mediterranean Region
(MR), an international collaboration aiming at under-
standing the burden of CVD and evaluating cost-effective
strategies to combat it was recently established. This paper
describes the rationale and methods of the project Med-
CHAMPS to disseminate this successful experience.
Methods The framework of MedCHAMPS is exceptional
in combining multiple disciplines (e.g. epidemiology,
anthropology, economics), countries [Turkey, Syria,
occupied Palestinian territory (oPt), Tunisia, UK, Ireland],
research methods (situational and policy analysis, quanti-
tative and qualitative studies, statistical modeling), and
involving local stakeholders at all levels to assess trends of
CVD/diabetes in the society and attributes of the local
health care systems to provide optimal policy recommen-
dations to reduce the burden of CVD/diabetes.
Results and conclusions MedCHAMPS provides policy
makers in the MR and beyond needed guidance about the
burden of CVD, and best cost-effective ways to combat it.
Our approach of building developed–developing countries
collaboration also provides a roadmap for other researchers
seeking to build research base into CVD epidemiology and
prevention in developing countries.
Keywords Cardiovascular disease  Diabetes 
Mediterranean Region  Trends  Population  Policies 
Interventions
Introduction
Non-communicable diseases (NCDs—particularly cardio-
vascular diseases (CVD), and type 2 diabetes) are increasingFor the MedCHAMPS collaboration.
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dramatically in the developing world. The rise of lifestyle-
related chronic disease in developing countries is the result of a
complex constellation of social, economic, and behavioral
factors driven by globalization, urbanization, and aging of
populations (Beaglehole and Yach 2003; Yach et al. 2005). For
example, the rise in lifestyles characterized by imbalance
between nutrition and physical activity and excessive use of
tobacco products is casting a heavy toll on the current and
future burden of CVD, and type 2 diabetes in these settings
(Beaglehole and Yach 2003; Yach et al. 2005). Currently,
CVD is the leading cause of morbidity and mortality world-
wide accounting for about 30 % of global deaths, with about
80 % of the CVD burden occurring in developing countries
(Rodgers and Vaughan 2002). On the other hand, more than
one billion adults worldwide are either overweight or obese
(World Health Organization 2011b), and 346 million are
affected by diabetes (mostly type 2), over two-thirds of whom
live in developing countries (World Health Organization
2011a). With future forecasts predicting increasing trends and
earlier onset of these diseases (Ezzati et al. 2005; Nugent
2008), the burden of CVD/diabetes will likely wreak havoc on
the prospects for economic development in developing coun-
tries, as well as on the livelihood of families and communities.
Most premature CVD and diabetes are avoidable by
adopting healthier diets, active lifestyles, and stopping
smoking, but intervening at these easy to identify targets has
proven to be challenging even in the best equipped health
systems. Moreover, knowledge of the most effective inter-
ventions to reduce CVD and diabetes comes mainly from
industrialized countries, and cannot be applied uncritically
in very different socio-cultural settings (Ebrahim and Smith
2001). Furthermore, health systems and services in most
developing countries, envisioned to tackle acute infectious
diseases, are often not ideally organized to promote effec-
tive care and prevention for chronic diseases, and the non-
governmental health sector usually focuses on clinical care
rather than health care or prevention (Maziak 2009).
The Mediterranean Region (MR) region has been rec-
ognized as a hot-spot for CVD and type 2 diabetes, where
projections of the burden of these diseases exceed those of
other regions, yet local data to inform health policy and
intervention are still inadequate (Alwan 1993; Maziak
2006; Murray and Lopez 1996; World health Organization
1999). Six out of the world’s top ten countries with the
highest prevalence of diabetes are in this region (Interna-
tional Diabetes Federation 2011). The incidence of CVD
and diabetes is generally showing an increasing trend in the
MR; about 47 % of the region’s current burden of disease
is considered to be due to NCDs, and the Global Burden of
Disease project has estimated that this will rise to about
60 % by the year 2020 (Murray and Lopez 1997).
Deaths from CVD in the MR, moreover, appear to be
occurring much earlier than in developed countries and to
affect men disproportionately, further compromising the
economic livelihood of families and communities in these
societies (Maziak et al. 2007; Yusuf et al. 2001). For
example in Syria, about half of CVD mortality is occurring
before the age of 65 years compared to one-fifth only
occurring before the age of 70 years for developed coun-
tries (Maziak et al. 2007; Reddy 2002).
Addressing CVD and diabetes in the MR requires inten-
sive work on their proximal individual risk factors (e.g.
hypertension, obesity, smoking), as well as wider environ-
mental and societal factors (e.g. policy, culture) (Rose 1985).
Therefore, local data about the status of CVD/diabetes in the
society and attributes of the local health care systems
including planners, providers and customers are needed to
guide interventions and policy options. Such local informa-
tion can be integrated within cutting edge modeling
techniques to provide optimal policy recommendations to
reduce the burden of CVD/diabetes in MR countries. One of
the more extensively studied and refined models is the
IMPACT model developed by collaborators on this project
(Capewell and colleagues originally in the UK, with vali-
dation studies conducted in a variety of populations)
(Capewell et al. 2000; Critchley et al. 2004; Ford et al. 2007;
Laatikainen et al. 2005; Unal, Critchley and Capewell 2004).
Project MedCHAMPS (Mediterranean Studies of Cardio-
vascular disease and Hyperglycemia: Analytical Modeling
of Population Socio-economic transitions) funded by the
EU-FP7 involves an international collaboration of institu-
tions in six countries (UK, Ireland, Turkey, Syria, oPt, and
Tunisia) to come up with effective policy recommendations,
both within and outside the health sector to reduce the burden
of CVD and diabetes in each partner MR country.
The importance of MedCHAMPS stems from (1) the
need to develop successful models of international col-
laboration to address the acute health needs of communities
in developing countries, (2) the adoption of an iterative
participatory approach toward understanding of local
health scene in the target MR countries, (3) the coupling of
this participatory approach with cutting-edge modeling
techniques to evaluate policy options and their feasibility,
and (4) the expected relevance of lessons emerging from
this project to other countries in the MR, and to developed–
developing countries collaborations to reduce the burden of
CVD/diabetes worldwide. This paper describes the ratio-
nale and methods of MedCHAMPS to inform other
potential collaborations to reduce CVD/diabetes morbidity
and mortality in developing countries. The framework is
exceptional in attempting to pull together scientists and
data from multiple disciplines and fields of study (e.g.
epidemiology, anthropology, economics) to understand the
burden of CVD in partner countries in the MR, as well as
recommend best effective and cost-effective policy options
to reduce CVD morbidity and mortality in the MR (Fig. 1).
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Objectives
Specifically, MedCHAMPS aims at:
1. Identifying data sources and future data requirements
in partner MR countries.
2. Developing a CVD/diabetes model for use within the
project countries to explain trends and predict likely
future impact of disease.
3. Defining the national policy context and characterizing
the health systems in partner countries in the MR.
4. Developing and evaluating policy options for partner
countries in the MR and supporting their implementation.
5. Disseminating the knowledge obtained in this project
to support the design and implementation of sustain-
able CVD/diabetes prevention and intervention
policies in partner as well as other countries in the MR.
Methods
Objective 1: identifying data sources and future data
requirements in partner MR countries
The first stage of the project involved obtaining and eval-
uating existing data sources relevant to CVD and diabetes
epidemiology in each of the four partner countries. A data
platform was developed to standardize the data require-
ments across the project. The data platform included the
definitions or cutoff points of all the patient groups, risk
factors and treatment uptake data. The tool was first
developed iteratively by exchanging e-mails then shared
with the partners for their comments and discussed with the
researchers in a training workshop. Using a pre-designed
data collection platform helped to clarify what kind of data
was needed to populate the IMPACT Models, and how this
data could be found in each study country.
A team of researchers in each country explored a variety
of nationally and locally available data sources including
census data, mortality data, household surveys, prescribing
data and hospital admissions data to identify and collate
existing available information on CVD/diabetes morbidity
and mortality, major risk factors for CVD/diabetes, and on
population and demographic profiles.
A second step was to critically appraise the quality of
available data, comparing these with standard international
guidelines (such as WHO STEPwise surveillance guide,
WHO Health Metrics Network) and making recommen-
dations regarding future collection of data, based on current
availability, and level of economic development. Summa-
ries of the data availability and quality within each country
were prepared by the MedCHAMPS researchers for each
WP8: Dissemination and Implementation
WP10: Project Management
WP4a-d: Data input, model analyses and validation 
in Palestine, Syria, Tunisia and Turkey
WP6a-d: 
Developing and 
evaluating policy 
options in 
Palestine, Syria, 
Tunisia and Turkey
W
P9: Training of junior researchers
WP2 Model data collection, 
analysis and critical appraisal
WP1: Project Framework and 
Methodology Development
WP3: Model development
WP5a-d: National 
situation analysis of 
current policy and 
health systems 
contexts in Palestine, 
Syria, Tunisia, and 
W
P7: Integration 
Fig. 1 Schematic depiction of
MedCHAMPS project activities
(2009–2012; Palestine, Syria,
Tunisia and Turkey) and their
relationship divided into 10
work packages (WP)
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country (detailed tables are available from the authors upon
request).
Objective 2: developing a CVD/diabetes model for use
within the project countries
During this second stage, data already collated and
appraised were used to populate a series of chronic disease
models (for CHD, ischemic stroke, and type 2 Diabetes), to
explain past trends in disease, and predict the likely future
impact of disease, under a number of different policy
scenarios.
The existing CHD IMPACT model was further devel-
oped and adapted to deal with an MR situation where CHD
rates may be increasing, using different absolute levels of
risk (based on case-fatality data from Tunisia). Two ‘‘new’’
Markov models were also developed to cover trends in
ischemic stroke and type 2 diabetes; these were validated
first with data readily available from Western populations,
and then with data from one of the partner countries
(Tunisia) before wider dissemination. Each of the three
models was then populated with data from the project
countries (collated during Objective 1). Each model was
then validated against observed trends or CVD levels in
each MR project country, performing sensitivity analysis
(using both simple methods, such as analysis of extremes,
and probabilistic methods) to identify key variables and
areas of uncertainty to which the models are particularly
sensitive. Data collection and entry are to some extent an
iterative process, as efforts were made to refine data esti-
mates for parameters shown to be most critical in the model
evaluations.
The IMPACT CHD model
Data on populations, mortality, patient groups and num-
bers, treatments and risk factor trends were collated and
critically appraised. The data were then integrated and
analyzed using IMPACT, a previously validated CHD
policy model (Capewell et al. 2000; Critchley et al. 2004;
Ford et al. 2007; Laatikainen et al. 2005; Unal, Critchley
and Capewell 2004). The model was initially used to
explain past CHD mortality trends in each of the four
countries, and validated by comparing with observed
trends.
The diabetes model
The model integrates population, obesity and smoking
trends for adults in each population, to estimate future
diabetes prevalence using a Markov approach. Model
parameters were derived from the literature. Diabetes
incidence was estimated using DISMOD II from the
baseline estimation of diabetes prevalence. The model
outputs were compared with subsequent diabetes preva-
lence surveys. The agreement was generally good.
Objective 3:defining the national policy context
and characterizing the health systems in partner
countries in the MR
This objective involved a ‘‘situation analysis’’, which
sought to integrate perspectives at different ‘levels’ of the
health system in each partner country, reflecting the con-
texts in which health systems manage CVD and diabetes.
This aimed to identify both gaps in policies as well as the
gaps on the ground or limitations in existing delivery of
services. Starting with established schematic frameworks
of potentially effective policy measures and health system
interventions for the prevention of CVD/diabetes, we
adopted a variety of techniques including document anal-
ysis, key informant interviews, clinic observation and
patient interviews to characterize the health service
response to CVD/DM. The first level (document analysis),
involved identifying, collating and systematically review-
ing relevant documentary materials on policies and health
services provision, with support from senior project
members and local stakeholders at various levels. Key
informant analysis (the second level) was then used to
explore perceptions and knowledge of relevant national
policies, and the constraints on their implementation
through interviews with senior personnel involved in
organizing or influencing the health system, clinicians in
the public and private sectors, members of professional
associations, non-governmental organizations, members of
the pharmaceutical industry, and the specialist media.
Finally, direct clinic observation (the third level) was car-
ried out in four selected clinics in each partner country,
including interviews with clinic staff to explore their
experience in treating NCD patients. The health beliefs and
treatment experience of NCD patients and their family
members were also explored through interviews, assessing
also whether these differed according to demographic,
gender or socio-economic stratification. The rationale for
this three-level design was to integrate a level of concep-
tualization as evidenced in policy documents, a level of
awareness as displayed by key informants, and a level of
practice revealed through clinic fieldwork. Document
analysis, taken on its own, portrays aspects of the health
system and the ways it is intended to function (whether
exemplified in an institutional organogram or a set of
protocols to guide treatment); but the portrayal is invari-
ably incomplete and depicts a situation in theory. Key
informants can help us to put flesh on the bones of this
theoretical depiction: they provide commentary on how the
health system works and is intended to work, and where the
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gaps and shortcomings are to be found. In doing so they
may take us a step toward understanding better how the
health system actually works. But key informants generally
speak from privileged positions, and are often selected
because of their ability to give an overview. Such a per-
spective is not well suited to understanding local realities,
especially outside the capital. For that, direct observation
and enquiry are necessary to gain an insight into local
practices, local obstacles and dilemmas, and the local
understanding of different kinds of actors (staff and
patients). In the context of MedCHAMPS, brief fieldwork
in four clinics per country was an attempt to provide a
preliminary ‘reading’ of clinic-based realities. No claims
can be made about the ‘representative’ sampling of clinics,
though the design envisaged a spread of public and private,
primary and secondary services, and urban and rural. But
we judged it a vital element in a situation analysis to
provide some details of the situation ‘on the ground’, to
triangulate with findings from the document analysis and
key informants. The concept of adherence in diabetes
treatment is a case in point, tracking from documents to
key informants to local practices and frustrations.
Objective 4: developing and evaluating policy options
and supporting their implementation in partner
countries
Following the completion of Objectives 2 and 3, a mixed
method approach was utilized to identify and evaluate a
series of potential policy options. This was based on the
results of the situation analysis and epidemiological
modeling described above. The situation analysis was
used to identify possible relevant policy options and to
test the feasibility and potential uptake of these policies,
while the epidemiological modeling allowed us to explore
the likely range of effectiveness of various selected policy
options. The exact policy options considered thus depen-
ded on the results of health system situational analysis in
each of the partner countries. Based on the input from
previously defined stakeholders, priorities were set for
each country. Selected policy options that can be modeled
were then evaluated using the adapted IMPACT models,
to undertake ‘‘what if’’ analyses in each study country,
quantifying their likely effectiveness. A full economic
evaluation was performed for one cross cutting policy
option (salt reduction): combinations of different inter-
ventions such as labeling, reformulation and educational
campaigns were costed based on methods developed in the
WHO Global Burden of Disease Project, and WHO-
CHOICE project (see www.who.int/choice/en/).
Costs of specific interventions for salt reduction were
collected in each country and combined with outcomes to
generate cost-effectiveness ratios, and subjected to
probabilistic sensitivity analyses to generate cost-effec-
tiveness acceptability curves based on net benefit
(quantifying uncertainty around each estimate). Outcomes
were expressed as deaths prevented or postponed (DPPs) or
life years gained (LYG) for resources expended. These
results were compared with other methodologies and
published studies to arrive at optimal policy recommen-
dations for partner countries. Having completed an
assessment of the costs of implementation of these selected
policy options, we were able to recommend policy changes
to relevant government departments based on consider-
ations of feasibility and effectiveness, and/or cost-
effectiveness, and finally assist with drawing up detailed
country specific plans for the implementation and evalua-
tion of the chosen high priority policy options. All these
processes were supported with empirical evidence.
Objective 5: dissemination and involvement of policy
makers
Major stakeholders (particularly international policy mak-
ers and researchers, national policy makers, and primary
stakeholders such as community members and organiza-
tions, health care providers, local health advocacy groups,
non-governmental organizations) have been involved and
targeted through consultation during the project and at
critical stages in particular. This activity is built into the
knowledge management strategy of MedCHAMPS to
maximize the relevance, acceptability and impact of the
findings disseminated. These key policy makers have been
explicitly involved in the project management and advisory
group, which met at least annually to review and discuss
the progress of the project. They also took part as ‘‘key
informants’’ in the situation and policy analysis, and have
also assisted with identifying and retrieving relevant doc-
uments for document analysis. Most critically, national
stakeholders were approached with results from the epi-
demiological modeling and situation analysis, before
commencing Objective 4 (option appraisal), to shape and
comment on the policy options to be budgeted and planned.
Specific activities were planned and conducted to dis-
seminate our findings, seek feedback about our work, and
induce policy changes. These included identification of key
project stakeholders in each of the partner countries; con-
sultation with national policy makers at all stages of the
project; conducting national meetings and workshops
aimed at sharing project findings and seeking feedback
from professionals and stakeholders; consultation with
health providers in each country about their experiences;
lectures, abstracts presented at national and international
scientific meeting; media and press releases devoted to the
dissemination of project findings; website development for
MedCHAMPS as a portal for information about the project
Cardiovascular disease in the Eastern Mediterranean
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and dissemination of project findings and experiences
(http://research.ncl.ac.uk/medchamps/index.html); scien-
tific publications in peer-reviewed journals; production of
policy-briefings for national and international policy mak-
ers; organization of national meetings for the dissemination
of project findings and stimulation of policy action.
Discussion
Several features of MedCHAMPS are methodologically
novel in terms of enhancing evidence-based policy making
within the Mediterranean Region. Most notably, it is the
combination of a detailed qualitative situation analysis,
epidemiological modeling using the best local data avail-
able (and making assumptions to ‘‘fill in the gaps’’ where
needed), and a cost-effectiveness analysis that is unique in
a middle income region with increasing burden of CVD
and diabetes (Murray et al. 2003) (Fig. 1).
In industrialized nations, disease models have been used
for some time to guide policy and strategy development at
various levels, but the approach is novel in the MR. In the
recent study by some in our team in a middle-income city
(Beijing, China) explored the feasibility of examining CHD
trends in the whole Beijing population of 13.8 million
(Critchley et al. 2004). Between 1984 and 1999, age
adjusted CHD mortality rates increased by approximately
50 % in men and 27 % in women aged 35–74, mostly as a
result of a substantial increase in total cholesterol levels
(1.05 mmol/l) consistent with an increasingly ‘Western-
ized’ diet (Critchley et al. 2004). While these results
demonstrate the feasibility of using the IMPACT method-
ology in a middle income setting, its application to the
local risk factor profile and culture of the MR brings
insights to guide CVD/diabetes prevention in this region
and cautiously beyond. We have also developed new
modeling platforms for type 2 diabetes and stroke for this
project, which allowed us to explore a greater range of
disease outcomes than previously and to base our chosen
policy options on estimates of the effectiveness and cost-
effectiveness of different interventions on risk factors for a
wide range of health outcomes related to CVD/diabetes.
The most extensive collection of original data for
MedCHAMPS was in the qualitative part of the research,
combining a national overview of health policy for CVD/
diabetes with the organization and provision of local health
services. The inclusion of an element of local data col-
lection in clinics, in the qualitative part of the research, is
guided by the need to understand how the guidelines and
interventions may be interpreted and applied in different
clinical and cultural contexts, as well as the need to balance
concerns with primary and secondary prevention. Crucial
as a focus on risk factors and primary prevention is for
MedCHAMPS’ overall aim, it was also important to keep
in mind the challenge for health systems which have to
manage the treatment of those who already have CVD/
diabetes. What are the pressures on services? How well
trained are staff to deal with the particular demands of
these chronic health problems? And how do patients access
services? These were questions addressed through brief
fieldwork in a number of clinics in each country. And while
such questions have been asked in other national contexts,
these are still new topics of research in the MR, involving
methodological skills and perspectives which are still rel-
atively novel and unfamiliar.
This in-depth understanding of local health care systems
coupled with the application of modeling techniques allows
us to identify prevention strategies that are most likely to
be effective and acceptable in reducing the burden of CVD/
diabetes in the MR. By quantifying the current and likely
future burden of CVD/diabetes and their related risk factors
in the target populations, MedCHAMPS maximizes the
effectiveness of existing resources (surveys of major CVD
and diabetes risk factors) in developing appropriate CVD/
diabetes policies in partner MR countries. The experience
from model building and policy analysis in Palestine,
Syria, Tunisia and Turkey is of great importance for other
countries in the MR, which share similar social, economic,
and cultural attributes. Moreover, our use of variety of
approaches (situation analysis, policy analysis, key infor-
mant interviews, secondary analyses of quantitative
surveys, qualitative and participatory studies, reviews of
documents and literature, model development and analysis;
Fig. 1) is generating much needed local capacity that can
take on the collection and analysis of data in key health
areas beyond the life of this project. Finally, MedCHAMPS
goes further than generating reliable evidence to guide
policy and local capacity by developing the implementa-
tion and future evaluation plans for recommended policies
in partner MR countries.
Conclusions
In summary, our results provide policy makers in partner
MR countries with a clear picture about the burden of CVD
in their countries, and best cost-effective ways to combat it.
They are likely to be of great importance for other coun-
tries in the MR, which share similar social, economic, and
cultural attributes. Finally, our approach of building
developed–developing countries collaboration taking
advantage of local expertise and knowledge coupled with
the application of advanced research methods provides a
roadmap for other researchers in developing countries
aiming to build research base into CVD epidemiology and
prevention.
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